Eirion Therapeutics is a clinical-stage biopharmaceutical company based in Woburn, Mass., developing next-generation prescription products for aesthetic dermatology. Its pipeline focuses on treatments for wrinkles, primary axillary hyperhidrosis, androgenic alopecia, and hair greying. The company is led by Jon Edelson, MD, who serves as Chairman, CEO, and President. Eirion plans to pursue additional indications that address other major unmet clinical needs for physicians and their patients. Financially, the company had previously raised approximately $11M via convertible notes, which will convert into Series A Preferred Stock in connection with the new financing. The recent Series A and licensing agreement with Haohai is structured to support development and commercialization efforts.

Total raised

$40M

Funding rounds

1

Latest round

Series A

Latest activity

Mar 2021